Clinical and Immunological Features of the CMV Infection Atypical Course in Immunocompetent Individuals

The Republican Research and Practical Center for Epidemiology and Microbiology

Status: Completed

Conditions: CMV

Treatments: Diagnostic Test: Bood leukocyte subsets; Diagnostic Test: CMV specific T-cells; Diagnostic Test: serum CMV IgM / IgG antibodies

Study type: Observational

Funder types: Other

Identifiers

NCT04392297

RRPCEM_CMV

Details and patient eligibility

About

Current study evaluates possible correlations between the content of various cell populations, the genetic material of the virus and antibodies to it in the blood of patients and the risk of thrombosis development in patients with acute CMV infection.

А new method for the early detection of immunological and clinical signs of thromboembolic complications of CMV infection in immunocompetent individuals and the treatment of patients in this category will be developed.

Full description

• evaluate the immune status main indicators that characterize the activation of immune system, immunosuppression and anergy (myeloid suppressor cells, T-regulatory cells, T-cells according to the stages of differentiation (naive - effector - memory), activated T-cells);
• identify and characterize immunological disorders in patients with CMV infection complicated by thromboembolism of various localization;
• determine the presence and quantitative content in plasma / serum and neutrophils of the CMV genetic material by real-time PCR;
• study humoral immunity to CMV (IgM / IgG antibodies to CMV in serum);
• determine the content of CMV specific T-cells in peripheral blood;
• develop a method for the early detection of immunological and clinical signs of thromboembolic complications of CMV infection in immunocompetent persons and treatment of patients in this category.

Enrollment: 45 patients

Sex: All

Ages: 18 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• age 18 - 80 years;
• fever of not clear etiology
• confirmed CMV infection

Exclusion criteria

• HIV infection
• taking hormones, cytostatics;
• drug addiction
• malignant neoplasms over the past 5 years.
• active viral hepatitis or liver cirrhosis;
• immunosuppressive conditions of any etiology

Trial design

45 participants in 1 patient group

Patients with CMV infection

Treatment:

Diagnostic Test: serum CMV IgM / IgG antibodies

Diagnostic Test: CMV specific T-cells

Diagnostic Test: Bood leukocyte subsets